Interesting announcement about CEO resignation on 3/3/14
The CEO is replaced by a newly formed executive committee consisting,among others,the chairman of the BOD,Director Robert Wilson......retired Vice Chairman of Johnson and Johnson(pretty large corp to my understanding....$300 BB mkt cap)....And Paul Friedman ....former CEO of INCY..a $9.5 BB mkt cap BIO Corp.
IMO,these guys are not novices and likely more competent (synergy) than the previous CEO.
It is also stated that the transition is not expected to create a delay in the advancement of Ganetespib or the HDC platform
IMO....the loss of the CEO does not create a vacuum and Bernitz's departure was in the best interest of SNTA.
These supposed negatives look like positives to me